A compendium of mutational cancer driver genes
A fundamental goal in cancer research is to understand the mechanisms of cell
transformation. This is key to developing more efficient cancer detection methods and …
transformation. This is key to developing more efficient cancer detection methods and …
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
C Zhu, X Guan, X Zhang, X Luan, Z Song, X Cheng… - Molecular cancer, 2022 - Springer
Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …
Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma
To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …
Synthetic lethality as an engine for cancer drug target discovery
A Huang, LA Garraway, A Ashworth… - Nature reviews Drug …, 2020 - nature.com
The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …
products that are recurrently mutated in specific cancer types. However, mutational analysis …
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
V Amodio, R Yaeger, P Arcella, C Cancelliere… - Cancer discovery, 2020 - AACR
Most patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) experience
clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer …
clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer …
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
YNP Chen, MJ LaMarche, HM Chan, P Fekkes… - Nature, 2016 - nature.com
The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an
important role in signal transduction downstream of growth factor receptor signalling and …
important role in signal transduction downstream of growth factor receptor signalling and …
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
RJ Nichols, F Haderk, C Stahlhut, CJ Schulze… - Nature cell …, 2018 - nature.com
Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide
spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E …
spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E …
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
DA Ruess, GJ Heynen, KJ Ciecielski, J Ai… - Nature medicine, 2018 - nature.com
The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …
Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer
MJ LaMarche, M Acker, A Argintaru… - Journal of medicinal …, 2020 - ACS Publications
SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is
involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays …
involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays …
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
S Mainardi, A Mulero-Sánchez, A Prahallad… - Nature medicine, 2018 - nature.com
RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-
small-cell lung cancers (NSCLCs),–. Inhibition of the RAS oncoproteins has proven difficult …
small-cell lung cancers (NSCLCs),–. Inhibition of the RAS oncoproteins has proven difficult …